Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual Event September 1, 2020 - 12:20pm (Eastern...
Antibe Therapeutics Inc.: - Phase II secondary data confirmed remarkable potency of ATB-346 - - 3rd party commercial studies project peak annual sales of $5.3 billion across seven key...
- ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain - - ATB-346 is more potent than expected; lowest effective dose still to be established - - Antibe plans pivotal...
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a...
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th for the fiscal quarter ended June 30, 2019. The...
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce its conference...
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany. CPhI Worldwide is the...
Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 28 for the fourth quarter and the year ended March 31, 2017. The...
Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from...
Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched PentOS OI™ Putty, the first product of a new family...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.405 | 0.405 | 0.405 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.405 | 0.405 | 0.405 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.405 | 0.405 | 0.405 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.405 | 0.405 | 0.405 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.405 | 0.405 | 0.405 | 0 | 0 | CS |
| 156 | 0 | 0 | 0.405 | 0.405 | 0.405 | 0 | 0 | CS |
| 260 | 0.025 | 6.57894736842 | 0.38 | 0.89 | 0.305 | 274773 | 0.52530339 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
